- £29.04m
- £15.38m
- £2.19m
REG - Angle PLC - Results of Eisai Phase 2 pilot study
AnnouncementREG - Angle PLC - Issue of LTIP Options and Share Options
AnnouncementRCS - Angle PLC - Novel findings using Parsortix
AnnouncementREG - Angle PLC - Analysis of CTC-DNA and ctDNA using Illumina assay
AnnouncementRCS - Angle PLC - Parsortix used in research paper from ETH Zurich
AnnouncementREG - Angle PLC - Trading Update
AnnouncementRCS - Angle PLC - HER2 presentation at SABCS
AnnouncementRCS - Angle PLC - Parsortix based PD-L1 assay showcased at AACR
AnnouncementRCS - Angle PLC - Research on HER2 assay kit showcased at AACR
AnnouncementRCS - Angle PLC - ANGLE presents two posters at EACR
AnnouncementRCS - Angle PLC - Parsortix enriched CTC & ctDNA in NSCLC patients
AnnouncementRCS - Angle PLC - Publication demonstrates CTC profiling potential
AnnouncementRCS - Angle PLC - 100th publication supporting Parsortix system use
AnnouncementREG - Angle PLC - Half-year Report
AnnouncementREG - Angle PLC - Exclusive agreement for DNA NGS panel
AnnouncementRCS - Angle PLC - Agreement with Recursion Pharmaceuticals
AnnouncementREG - Angle PLC - Notice of Interim Results and Webcast
AnnouncementRCS - Angle PLC - Data supporting FDA approval published in Journal
AnnouncementRCS - Angle PLC - Independent Parsortix study
Announcement